摘要
前列腺癌(PCa)给社会带来的负担越来越大。晚期PCa患者缺乏有效治疗和预后不良,迫切需要新的和改进的药物鉴定。这是由于该疾病的高分子异质性和复杂的分子病理生理学的阻碍,导致药物在少数患者有效和癌症发展耐药性。新药的发现已经被证明是复杂和具有挑战性的。随着技术的进步(主要与组学方法有关),可以全面描述疾病背后的分子变化,并考虑到生物信息学的各自发展,计算药物再利用已经成为缩短从发现到临床应用和解决疾病分子复杂性的一种有前途的方法。在这篇文章中,我们旨在回顾最近的研究,通过对分子图谱(组学)数据的研究和药物再利用策略的应用来定义用于PCa的药物/化合物。本文还简要概述了技术要求和与后者相关的挑战。为此目的,我们使用PubMed数据库进行了文献搜索。许多药物/化合物已经被提出作为潜在的PCa疗法,主要基于基因组学和转录组学数据的调查。在大多数情况下,需要在疾病模型中进行进一步的评估。由于最终蛋白质是药物的靶点,因此扩展蛋白质组学分析数据的使用(单独或与其他组学结合)有望进一步确定用于PCa的新药物或改用药物。
关键词: 药物候选,药物再利用,分子标记,组学,个体化药物,前列腺癌。
Current Medicinal Chemistry
Title:Developing Novel Drug Candidates and Repurposed Drugs for Prostate Cancer Based on Molecular Profiles
Volume: 28 Issue: 40
关键词: 药物候选,药物再利用,分子标记,组学,个体化药物,前列腺癌。
摘要: Prostate cancer (PCa) carries a growing burden on society. Lack of curative treatment and poor prognosis among patients with advanced PCa imply an urgent need for novel and improved drug identification. This is hampered by the disease's high molecular heterogeneity and complex molecular pathophysiology, resulting in drugs being efficient in a few patients and cancer developing resistance to treatment. De novo drug discovery has proven to be complex and challenging. Along with technological advancements (mainly linked to –omics approaches) that allow for comprehensive characterization of the molecular changes underlying disease, and considering respective developments in bioinformatics, computational drug repurposing has emerged as a promising approach to shorten the way from discovery to clinical application and address the disease molecular complexity. With this article, we aimed at reviewing recent studies in which drugs/ compounds for PCa were defined through the investigation of molecular profiling (-omics) data and the application of drug repurposing strategies. A brief overview of the technical requirements and associated challenges with the latter are also provided. For that purpose, a literature search was conducted using the PubMed database. Numerous drugs/ compounds have been proposed as potential PCa therapeutics, mostly based on the investigation of genomics and transcriptomics data. In most cases, further assessment in disease models is required. Since ultimately proteins are targeted by drugs, expanding on the use of proteomics profiling data (alone or in combination with other –omics) is expected to advance further defining new/repurposed drugs for PCa.
Export Options
About this article
Cite this article as:
Developing Novel Drug Candidates and Repurposed Drugs for Prostate Cancer Based on Molecular Profiles, Current Medicinal Chemistry 2021; 28 (40) . https://dx.doi.org/10.2174/0929867328666210525162730
DOI https://dx.doi.org/10.2174/0929867328666210525162730 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements